Han E, et al. – The goal of this study was to examine trends in use and payment of ophthalmic services in the Medicare population for years 2012 and 2013. Medicare Part B reimbursement for ophthalmologists was primarily driven by the utilization of anti–Vascular Endothelial Growth Factor (anti–VEGF) injections from 2012 to 2013. Of the total drug payments to ophthalmologists, biologic anti–VEGF agents ranibizumab and aflibercept accounted for 95% of all drug reimbursement. This is in contrast to other specialties in which drug reimbursement represented only a small portion of Medicare reimbursement.